Preclinical imaging refers to the use of various imaging modalities to visualize and study the biological processes in animals before clinical trials. These systems help researchers to gain insight into disease mechanisms, evaluate potential drug candidates, and monitor treatment efficacy. Technology advancement in the field of imaging is playing a crucial role in driving the growth of the global preclinical imaging market.
Modern imaging technologies, such as high-resolution magnetic resonance imaging (MRI), micro-computed tomography (micro-CT), and advanced ultrasound provide researchers with clearer and more detailed images of biological structures. The integration of multimodal imaging systems is another advancement in the preclinical imaging market as these systems combine multiple imaging techniques, such as PET-CT or PET-MRI, to provide complementary information and enhance the accuracy of preclinical studies which allows researchers to investigate multiple aspects of a disease or treatment simultaneously, leading to more comprehensive and reliable results.
Furthermore, there have been significant improvements in image analysis and data processing algorithms. Advanced software tools and machine learning algorithms enable researchers to extract quantitative data from images, automate image processing tasks, and improve the accuracy and efficiency of data analysis. These advancements save time and enhance the reproducibility and reliability of preclinical studies
Access Full Report at @ https://www.databridgemarketresearch.com/jp/reports/global-preclinical-imaging-market
Data Bridge Market Research analyses that the Global Preclinical Imaging Market is expected to grow with a CAGR of 6.3% in the forecast period from 2023 to 2030, and is expected to reach USD 3,299,734.83 thousand by 2030.
Key Findings of the Study
Increasing Incidence of Chronic Diseases May Drive the Market Growth
Chronic diseases, such as cancer, cardiovascular diseases, and neurological disorders, are a significant burden on healthcare systems worldwide. Preclinical imaging plays a vital role in understanding the underlying mechanisms of these diseases and developing effective therapeutic interventions.
Preclinical imaging offers valuable insights into disease progression, treatment response, and the evaluation of potential drug candidates. It allows researchers to visualize and study biological processes in animal models, providing a better understanding of disease mechanisms and aiding in the development of targeted therapies. Preclinical imaging helps streamline the drug development process and reduces the risk of failure in clinical trials by non-invasively monitoring disease progression and treatment efficacy.
The increasing incidence of chronic diseases has created a strong demand for innovative and effective treatment options. Pharmaceutical companies and research institutions are leveraging preclinical imaging technologies to accelerate the development of novel therapies. Imaging modalities such as micro-CT, MRI, and PET provide detailed anatomical and functional information, enabling researchers to track disease progression, evaluate treatment response, and assess the safety and efficacy of potential therapeutics.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022 (Customizable to 2015-2020)
|
|
Historic Years
|
2021
|
|
Quantitative Units
|
Revenue in USD Thousand and Pricing in USD
|
|
Segments Covered
|
Product (Systems and Services), Reagent (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, and Preclinical CT Contrast Agents), Application (Research and Development, Drug Discovery, Bio-Distribution, Cancer Cell Detection, BioMarkers, and Others), End User (Contract Research Organization, Pharmaceutical & Biotech Companies, Academic & Government Research Institutes, Diagnostics Center, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, Switzerland, Netherlands, Belgium, Turkey, Russia, Rest of Europe, China, Japan, Australia, South Korea, India, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, U.A.E., Israel, Saudi Arabia, Egypt, and Rest of Middle East and Africa
|
|
Market Players Covered
|
PerkinElmer Inc. (U.S.), FUJIFILM Corporation (Japan), Hologic, Inc. (U.S.), Bruker (Germany), Zeiss International (Germany), Agilent Technologies, Inc (U.S.)., Hamamatsu Photonics K.K. (U.S.), SOFIE (U.S.), Cubresa Inc. (Canada), Vieworks Co., Ltd. (South Korea), LI-COR (U.S.), Inc., Aspect Imaging Ltd. (Israel), Berthold Technologies GmbH & Co.KG (Germany), MILabs B.V (Netherlands), Trifoil Imaging (U.S.), Mediso Ltd (Hungary)., IVIM Technology Inc. (South Korea), MR Solutions (U.K.), Advanced Molecular Vision, Inc (U.S.), AI4R (France), Photon etc (Canada), and KUB TECHNOLOGIES INC (U.S.).
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global preclinical imaging market is segmented into four notable segments based on product, reagents, application, and end user.
- On the basis of product type, the market is segmented into systems and services
In 2023, the systems segment is expected to dominate the market with a market share of 66.42%
In 2023, the system segment is expected to dominate the market with a market share of 66.42% as it provides comprehensive, integrated, and efficient imaging solutions that facilitate multimodal imaging and enhance the research capabilities of scientists in preclinical studies.
- On the basis of reagents, the market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents
In 2023, the preclinical optical imaging reagents segment is expected to dominate the market
In 2023, the preclinical optical imaging reagents segment is expected to dominate the market with a market share of 41.09% as it provides non-invasive, real-time, and targeted visualization of specific molecules and cellular processes in small animals.
- On the basis of application, the market is segmented into research and development, drug discovery, bio-distribution, cancer cell detection, bio-markers, and others. In 2023, the research and development segment is expected to dominate the market with a market share of 35.59%
- On the basis of end user, the market is segmented into contract research organization, pharmaceutical & biotech companies, academic & government research institutes, diagnostics center, and others. In 2023, the contract research organization segment is expected to dominate the market with a market share of 49.24%
Major Players
Data Bridge Market Research analyses PerkinElmer Inc. (U.S.), FUJIFILM Corporation (Japan), Hologic, Inc. (U.S.), Bruker (Germany), and Zeiss International (Germany) as the market players in the market
Market Developments
- In November 2022, Bruker announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging. This helped the organization develop more revenue
- In May 2022, FUJIFILM Corporation announced the launch of Vevo F2, the world’s first ultra-high to low frequency (71MHz-1MHz) ultrasound and photoacoustic imaging system for preclinical use. The Vevo F2 features HD image processing technology and introduces a completely new signal pathway – from transducer to display screen. This enabled better image clarity, and when combined with multi-line processing, delivered significantly improved frame rates over earlier-generation platforms
- In April 2022, PerkinElmer, Inc. announced the expansion of its in vivo imaging portfolio with the launch of the Vega imaging system. This increased the company's product portfolio and overall revenue
- In December 2021, Battery Ventures, a global, technology-focused investment firm, acquired LI-COR Biosciences, an industry-leading company that makes highly engineered instrumentation systems for environmental research, agriculture, drug discovery, protein research, and therapeutics development
- In October 2021, MR Solutions announced the launch of a new AI that revolutionizes Magnetic Resonance Imaging (MRI) for preclinical research. This helped the organization develop more revenue
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, Switzerland, Netherlands, Belgium, Turkey, Russia, rest of Europe, China, Japan, Australia, South Korea, India, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, U.A.E., Israel, Saudi Arabia, Egypt, and rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the fastest-growing and dominant region in the global preclinical imaging market during the forecast period 2023 - 2030
North America is expected to dominate the global preclinical imaging market because of the higher level of investments by various manufacturers and increasing technological advancements in the region. North America is estimated to dominate the global preclinical imaging market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. The growing adoption of advanced technology and the launch of new products in this region.
For more detailed information about the global preclinical imaging market report, click here – https://www.databridgemarketresearch.com/jp/reports/global-preclinical-imaging-market
